KALA Pharmaceuticals, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing also provides unaudited quarterly results, including Q4 2020. The company is an ophthalmology-focused biopharmaceutical company; its two approved U.S. products are INVELTYS and EYSUVIS.
Business context and developments
- INVELTYS treats post-operative inflammation and pain following ocular surgery and has been marketed since January 2019.
- EYSUVIS, approved by the FDA in October 2020 for short-term treatment of dry-eye signs and symptoms, began shipping to wholesalers in late December 2020. Its full promotional launch began in January 2021.
- The company’s other programs—retinal-disease rTKIs, SEGRMs and surface-targeted steroid KPI-333—were in preclinical development. SEGRMs were in lead optimization, with a development candidate targeted for 2021.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Net product revenue | $6.4 million | $6.1 million |
| Cost of product revenue | $3.2 million | $2.0 million |
| Gross profit / gross margin | $3.2 million / approximately 50% | $4.1 million / approximately 67% |
| SG&A | $81.1 million | $65.0 million |
| Research and development | $18.4 million | $27.3 million |
| Operating loss | $96.2 million | $88.2 million |
| Net loss | $104.3 million | $94.3 million |
| Net loss per share | $1.99 | $2.76 |
| Cash used in operating activities | $90.7 million | $92.7 million |
- Q4 2020 revenue was $2.24 million and net loss was $31.1 million, compared with Q4 2019 revenue of $1.18 million and net loss of $22.0 million.
- Revenue rose modestly year over year, including initial EYSUVIS shipments and higher INVELTYS unit pricing, but lower INVELTYS unit sales related to fewer elective surgeries offset growth. Gross margin declined, reflecting higher product costs and an inventory reserve.
- SG&A increased $16.1 million, mainly from EYSUVIS launch preparation, administrative costs and stock-based compensation. R&D fell $8.9 million, largely because EYSUVIS Phase 3 spending decreased.
- At year-end, cash and cash equivalents were $77.3 million and short-term investments were $76.3 million, totaling $153.5 million. Working capital was $149.2 million. Total assets were $221.6 million; stockholders’ equity was $100.0 million.
- Outstanding debt principal was $75.0 million, secured by substantially all assets and bearing 9.875% annual interest. Principal installments begin in October 2022; maturity is October 2024. The company reported covenant compliance at year-end.
- FY2020 financing provided $160.6 million in net cash, including $125.4 million from an underwritten stock offering and $33.1 million from ATM sales. Shares outstanding increased from 36.1 million to 58.9 million during 2020. January 2021 ATM sales raised a further $18.2 million.
Outlook, risks and unusual items
- Management estimated year-end cash, investments, anticipated INVELTYS revenue and January 2021 ATM proceeds would fund operations, lease and debt service, and capital needs into at least Q4 2022; anticipated EYSUVIS revenue was expected to extend runway. This estimate depends on assumptions and could prove inaccurate. The financial statements state funding sufficiency for at least 12 months from issuance.
- No numerical revenue or earnings guidance is provided. Management expected commercialization expenses to rise, including a planned sales-force expansion from 91 to approximately 125 territory managers in 2021, subject to the pandemic. It expected R&D costs to decrease in 2021 versus 2020, while potentially increasing as pipeline programs advance.
- COVID-19 reduced elective ocular surgeries and INVELTYS demand, restricted sales-force access to clinicians and affected early research operations. Further disruption to sales, product launch, suppliers or markets remained uncertain.
- Notable items included a $1.0 million reserve for excess INVELTYS inventory attributed to COVID-19 and a $0.1 million write-off of EYSUVIS units that failed quality inspection. EYSUVIS-related revenue was highly concentrated among three customers, representing 35%, 32% and 29% of that product’s revenue.
- Key risks include persistent operating losses and negative operating cash flow, reliance on two products with limited commercial history, reimbursement and market-acceptance uncertainty, customer concentration, third-party manufacturing dependence, substantial debt, potential dilution, and the early stage of the pipeline. Accumulated deficit was $399.8 million. The company reported no material legal proceedings; management concluded disclosure controls and internal control over financial reporting were effective.
Important facts for investors to verify
- Whether EYSUVIS launch uptake, payer coverage, pricing and repeat prescribing translate into meaningful net revenue, and how much sales remain concentrated among a few wholesalers.
- Whether elective surgeries and INVELTYS demand recover, and whether COVID-19 or other disruptions affect clinician access, manufacturing or supply.
- Actual cash burn and progress against the stated runway estimate, including the effect of launch spending, debt service and any additional equity issuance.
- Debt covenant compliance, scheduled principal payments, collateral provisions and the impact of the 9.875% interest rate.
- Inventory quality, shelf life and purchase commitments, including the $48.0 million aggregate minimum supply purchase commitments disclosed through the contract term.
- Progress, timelines and funding needs for the preclinical pipeline; the filing provides no clear clinical-stage milestones beyond the stated SEGRM candidate target.